Evidence map›Paper›PMID 38167095›Full record

SynthesisRadiation oncology (London, England)2024

Stereotactic body radiotherapy for early-stage lung cancer: a systematic review on the choice of photon energy and linac flattened/unflattened beams.

Ashlesha Gill, Andrew L Hirst, Pejman Rowshanfarzad, Suki Gill, Nicholas Bucknell, Joshua Dass, Mahsheed Sabet

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Radiation oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ashlesha GillSchool of Physics, Mathematics and Computing, The University of Western Australia, Crawley, WA, 6009, Australia. ashlesha.gill@research.uwa.edu.au.ORCID http://orcid.org/0000-0002-7981-3236
Andrew L HirstDepartment of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, 6009, Australia.ORCID http://orcid.org/0000-0002-4050-0777
Pejman RowshanfarzadSchool of Physics, Mathematics and Computing, The University of Western Australia, Crawley, WA, 6009, Australia.ORCID http://orcid.org/0000-0001-8306-7742
Suki GillSchool of Physics, Mathematics and Computing, The University of Western Australia, Crawley, WA, 6009, Australia.ORCID http://orcid.org/0000-0001-9755-7232
Nicholas BucknellDepartment of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, 6009, Australia.
Joshua DassDepartment of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, 6009, Australia.
Mahsheed SabetSchool of Physics, Mathematics and Computing, The University of Western Australia, Crawley, WA, 6009, Australia.ORCID http://orcid.org/0000-0003-1050-0749
The University of Western Australia · AUSir Charles Gairdner Hospital · AUThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SBRT is an effective local treatment for patients with early-stage non-small cell lung cancer (NSCLC). This treatment is currently used in patients who have poor lung function or who decline surgery. As SBRT usually has small PTV margins, reducing the beam-on-time (BOT) is beneficial for accurate dose delivery by minimising intrafraction motion as well as improved patient comfort. Removal of the linear accelerator flattening filter can provide a higher dose rate which results in a faster treatment. In addition, the choice of photon energy can also affect the dose distribution to the target and the organs-at-risk (OAR). In this systematic review, studies analysing the choice of various photon beam energies, with a flattening filter or flattening filter free (FFF), were compared for their overall dosimetric benefit in the SBRT treatment for early-stage NSCLC. It was found that FFF treatment delivers a comparatively more conformal dose distribution, as well as a better homogeneity index and conformity index, and typically reduces BOT by between 30 and 50%. The trade-off may be a minor increase in monitor units for FFF treatment found in some studies but not others. Target conformity and OAR sparing, particularly lung doses appear better with 6MV FFF, but 10MV FFF was marginally more advantageous for skin sparing and BOT reduction. The favourable beam modality for clinical use would depend on the individual case, for which tumour size and depth, radiotherapy technique, as well as fractionation scheme need to be taken into account.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsRadiosurgeryRadiotherapy, Intensity-ModulatedSmall Cell Lung CarcinomaHumansLungRadiotherapy DosageRadiotherapy Planning, Computer-AssistedLung cancerPhoton energyRadiotherapySABRSBRT

Identifiers

PMID38167095
PMCPMC10762943
OpenAlexW4390496527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.